This invention is directed to a pharmacologically acceptable composition for inhibiting or treating hemorrhagic shock in a mammal. The composition includes a K.sub.ATP inhibitor and a pharmacologically acceptable carrier, with the K.sub.ATP inhibitor being present in an amount sufficient to inhibit or treat hemorrhagic shock in the mammal. The invention is also directed to a method for inhibiting or treating hemorrhagic shock in a mammal. The method includes administering to the mammal an amount of a K.sub.ATP channel inhibitor sufficient to inhibit or treat hemorrhagic shock in the mammal. In a preferred form of the invention, the K.sub.ATP channel inhibitor is selected from the group consisting of a sulfonylurea, a guanidine, a phenothiazine, an imidazoline, TMB-8 (also known as (8-N, N-diethylamino) octyl-3,4,5-trimethoxybenzoate), 2,3-butanedione monoxime, disopyramide, gliquidone, chlorpromazine, AMP-NPP (also known as 5'-adenylylamidodiphosphate), flecainide, MS-551 (also known as 1,3-dimethyl-6-(2-[N-(2-hydroxyethyl)-3-(4-nitrophenyl) propylamino]ethylamino)-2,4(1H,3H)-pyrimidinedione HCl) and combinations thereof.

guanidine/hemorrhage

Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus